Chronic Migraine Clinical Trial
— PREVENTIONOfficial title:
A Phase 2, Double-blind, Randomized, Multicenter, Placebo-controlled, Three Arm Parallel Study to Evaluate the Efficacy and Safety of TNX-1900 (Intranasal Oxytocin) in Patients With Chronic Migraine (PREVENTION Study)
Verified date | March 2024 |
Source | Tonix Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 2, double-blind, randomized, multicenter, placebo-controlled, three arm parallel study to evaluate the efficacy and safety of two different dosages (30 IU daily and 60 IU daily) of TNX-1900 in patients with chronic migraine.
Status | Completed |
Enrollment | 88 |
Est. completion date | October 23, 2023 |
Est. primary completion date | October 8, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Major Inclusion Criteria: - Men and women aged 18 to 65 years, inclusive, at the time of Visit 1. - History of migraine with or without aura for at least 1 year and onset at < 50 years of age. Patient must also have a history of chronic migraine > 3 months prior to Visit 1 as defined by IHS ICHD-3 - Patients can be on stable = 1 preventive medication and any number of abortive migraine medications for 90 days prior to Screening and during the study. All treatments, other than the study drug, thought to have preventive efficacy in migraine should not be started or discontinued during the entire study period. Note: Up to approximately 30% of the patients randomized into the study can be on 1 preventative medication. Once this category is filled, only patients who are not on any preventative medications can be randomized into the study. Major Exclusion Criteria: - History of cluster headache. - Presence of headaches more than 26 days a month on average for the 6 months prior to Screening. - Failed to benefit from an adequate dose and duration, in the investigator's judgment (eg, one month of ß-blocker), of 3 or more migraine preventive medications. - Use of opiates or barbiturates more than 4 days per month for more than 3 consecutive months prior to Visit 1 and during the study. - Use of over-the-counter (OTC) nasal products (ie, saline spray, Neti-Pot, Naväge® etc.) during the study. - Any use of intranasal corticosteroid medications or conditions in which use of intranasal corticosteroids may be indicated during the study, eg, unstable allergic rhinitis that has previously required intranasal corticosteroids. Intranasal corticosteroid use is not allowed within 28 days of Baseline/Randomization/Visit 2 and during the treatment phase or follow-up period of the study. - Patients who recently discontinued treatment with an anti-calcitonin-gene-related peptide (CGRP) or participated in anti-CGRP clinical study must be at least 4 months from the last drug administration prior to Visit 1. |
Country | Name | City | State |
---|---|---|---|
United States | Michigan Headache & Neurological Institute | Ann Arbor | Michigan |
United States | Austin Clinical Trial Partners | Austin | Texas |
United States | Boston Clinical Trials, Inc. | Boston | Massachusetts |
United States | Charlottesville Medical Research, LLC | Charlottesville | Virginia |
United States | Diamond Headache Clinic | Chicago | Illinois |
United States | DelRicht Research - Gulfport Memorial | Gulfport | Mississippi |
United States | Peters Medical Research | High Point | North Carolina |
United States | Clinical Neuroscience Solutions, Inc. | Jacksonville | Florida |
United States | Clinical Investigation Specialists, Inc. | Kenosha | Wisconsin |
United States | Alliance for Multispecialty Research - Las Vegas | Las Vegas | Nevada |
United States | Synergy Research Centers - Synergy San Diego | Lemon Grove | California |
United States | Preferred Research Partners, Inc. | Little Rock | Arkansas |
United States | Clinical Neuroscience Solutions, Inc. | Memphis | Tennessee |
United States | Segal Trials - Miami Lakes Medical Research Outpatient Site | Miami Lakes | Florida |
United States | DelRicht Research - LCMC Health Urgent Care | New Orleans | Louisiana |
United States | Coastal Carolina Research Center | North Charleston | South Carolina |
United States | Excell Research | Oceanside | California |
United States | IPS Research Company, INC. | Oklahoma City | Oklahoma |
United States | Clinical Neuroscience Solutions, Inc. | Orlando | Florida |
United States | DelRicht Research - Neighborhood Health | Prairieville | Louisiana |
United States | Clinvest Research | Springfield | Missouri |
United States | Viking Clinical Research, LTD | Temecula | California |
United States | DelRicht Research - Grassroots Healthcare | Tulsa | Oklahoma |
United States | Integrated Clinical Trial Services, Inc. | West Des Moines | Iowa |
United States | Alliance for Multispecialty Research - Wichita West | Wichita | Kansas |
United States | Upstate Clinical Research Associates, LLC | Williamsville | New York |
Lead Sponsor | Collaborator |
---|---|
Tonix Pharmaceuticals, Inc. | Premier |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean change in the number of monthly migraine headache days | Mean change in the number of monthly migraine headache days from the last 28 days of Baseline to the last 28 days of treatment (ie, month 3). A migraine headache day is any calendar day (0:00 to 23:59) in which the patient records in the e-diary:
An attack lasting 4 hours or more and meeting the ICHD-3 criteria for migraine without aura, or A migraine with aura, or An attack that meets ICHD-3 criteria for probable migraine, (a migraine subtype fulfilling all but one criteria (B-D) for migraine without aura), or An attack of any duration that was believed by the patient to be a migraine and was relieved by a triptan, ergot derivative, or other migraine-specific abortive medication. |
Last 28 days before Visit 2 (Day 1) and last 28 days before Visit 5 (Week 12) | |
Secondary | Proportion of patients experiencing a = 50% reduction in the number of migraine headache days | Proportion of patients experiencing a = 50% reduction in the number of migraine headache days from the last 28 days of Baseline to the last 28 days of treatment in each treatment group | Last 28 days before Visit 2 (Day 1) treatment and last 28 days before Visit 5 (Week 12) | |
Secondary | Mean change in the number of days using rescue medication | Mean change in the number of days using rescue medication (triptan, ergot derivative, or other migraine-specific acute medication) from the last 28 days of Baseline to the last 28 days of treatment. | Last 28 days before Visit 2 (Day 1) treatment and last 28 days before Visit 5 (Week 12) | |
Secondary | Patient Global Impression of Change (PGIC) | Proportion of patients with a Patient Global Impression of Change (PGIC) of 1, "very much improved", or 2, "much improved", at Week 12. Scores range from 1 to 7. Lower scores indicate more improvement. | Visit 5 (Week 12) | |
Secondary | Mean change in the number of moderate or severe headache days | Mean change in the number of moderate or severe headache days from the last 28 days of Baseline to the last 28 days of treatment. A moderate or severe headache day is defined as any calendar day wherein a patient records a headache or migraine of moderate or severe peak intensity in the e-diary. | Last 28 days before Visit 2 (Day 1) and last 28 days before Visit 5 (Week 12) | |
Secondary | Mean change in the number of migraine headache days | Mean change in the number of migraine headache days from the last 28 days of Baseline to average number per 28 days over the entire 12-week duration of Treatment Period. | Last 28 days before Visit 2 (Day 1) and average per 28 days over 12-week Treatment Period | |
Secondary | Mean change from Baseline in the Migraine-Specific Quality of Life Questionnaire | Mean change from Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) at Week 12. Scores range from 0 to 100. Higher scores indicate better quality of life. | Visit 2 (Day 1) and Visit 5 (Week 12) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05720819 -
Biofeedback-VR for Treatment of Chronic Migraine
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Completed |
NCT02514148 -
Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients
|
N/A | |
Enrolling by invitation |
NCT02291380 -
A Study to Evaluate Botulinum Toxin Type A for Injection(HengLi®)for Prophylactic Treatment of Chronic Migraine
|
Phase 3 | |
Withdrawn |
NCT02122744 -
RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine
|
N/A | |
Completed |
NCT02122237 -
Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial
|
Phase 3 | |
Recruiting |
NCT02202486 -
Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI
|
N/A | |
Completed |
NCT01709708 -
Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine
|
Phase 4 | |
Completed |
NCT01741246 -
Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging
|
N/A | |
Completed |
NCT01090050 -
Treximet in the Treatment of Chronic Migraine
|
Phase 4 | |
Recruiting |
NCT03507400 -
Introvision for Migraine and Headaches
|
N/A | |
Completed |
NCT04161807 -
Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
|
N/A | |
Completed |
NCT03175263 -
OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain
|
N/A | |
Withdrawn |
NCT04353505 -
Intra-arterial Sphenopalatine Ganglion Block for Patients With Refractory Headache
|
Phase 1 | |
Completed |
NCT01700387 -
A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency
|
Phase 4 | |
Completed |
NCT01667250 -
Non-Invasive Neurostimulation for the Prevention of Chronic Migraine
|
N/A | |
Not yet recruiting |
NCT01135784 -
Study of MIGRA-ZEN RELIEF PLUS In the Treatment of Chronic Migraine Headache
|
Phase 2 | |
Completed |
NCT01496950 -
Double-blind Randomized Clinical Trial of Transcranial Magnetic Stimulation in Chronic Migraine
|
Phase 1 |